




Contents lists available at ScienceDirect

## Travel Medicine and Infectious Disease

journal homepage: [www.elsevier.com/locate/tmaid](http://www.elsevier.com/locate/tmaid)

## Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean

Diego Urrunaga-Pastor<sup>a</sup>, Guido Bendezu-Quispe<sup>b,c</sup>, Percy Herrera-Añazco<sup>c,d</sup>,  
 Angela Uyen-Cateriano<sup>e</sup>, Carlos J. Toro-Huamanchumo<sup>f,g</sup>, Alfonso J. Rodriguez-Morales<sup>h,i,j,\*\*</sup>,  
 Adrian V. Hernandez<sup>k,l</sup>, Vicente A. Benites-Zapata<sup>c,f,\*</sup>

<sup>a</sup> Universidad Científica del Sur, Lima, Peru<sup>b</sup> Universidad Privada Norbert Wiener, Lima, Peru<sup>c</sup> Red Internacional en Salud Colectiva y Salud Intercultural, México, Mexico<sup>d</sup> Universidad Privada San Juan Bautista, Lima, Peru<sup>e</sup> Medecins Sans Frontieres, Health Politics, Brussels, Belgium<sup>f</sup> Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola (USIL), Lima, Peru<sup>g</sup> Clínica Avendaño, Unidad de Investigación Multidisciplinaria, Lima, Peru<sup>h</sup> Latin American Network of COVID-19 Research (LANCOVID), Pereira, Risaralda, Colombia<sup>i</sup> Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Americas, Pereira, Risaralda, Colombia<sup>j</sup> Universidad Privada Franz Tamayo (UNIFRANZ), Cochabamba, Bolivia<sup>k</sup> Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT, 06269, USA<sup>l</sup> Unidad de Revisiones Sistemáticas y Metaanálisis, Guías de Práctica Clínica y Evaluaciones Tecnológicas Sanitarias, Universidad San Ignacio de Loyola (USIL), Lima, Peru

## ARTICLE INFO

## Keywords:

COVID-19  
 SARS-CoV-2  
 COVID-19 vaccines  
 Vaccination  
 Vaccination refusal  
 Latin America

## ABSTRACT

**Background:** Determinants of vaccine acceptance are multifactorial, complex, and in most cases, context-dependent. We determined the prevalence of COVID-19 vaccination intention (VI) and fear of its adverse effects (FAE) as well as their associated factors in Latin America and the Caribbean (LAC).

**Methods:** We conducted a secondary cross-sectional analysis of a database collected by the University of Maryland and Facebook. We included participants aged 18 and over from LAC surveyed, January 15 to February 1, 2021. We evaluated VI, FAE, sociodemographic characteristics, COVID-19 symptomatology, compliance with community mitigation strategies, food and economic insecurity, mental health evaluation and the influence in VI when recommended by different stakeholders. We calculated crude and adjusted prevalence ratios with their 95% CIs.

**Results:** We analyzed 472,521 responses by Latin American adults, finding a VI and FAE prevalence of 80.0% and 81.2%, respectively. We found that female and non-binary genders were associated with a lower probability of VI and a higher probability of FAE. Besides, living in a town, village or rural area and economic insecurity was associated with a higher FAE probability. The fears of becoming seriously ill, a family member becoming seriously ill from COVID-19 and having depressive symptoms were associated with a higher probability of VI and FAE.

**Conclusion:** Eight out of 10 adults in LAC have VI and FAE. The factors identified are useful for the development of communication strategies to reduce FAE frequency. It is necessary to guarantee mass vaccination and support the return of economic activities.

\* Corresponding author. Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola (USIL), Lima, Peru.

\*\* Corresponding author. Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Americas, Pereira, Risaralda, Colombia.

E-mail addresses: [alfonso.rodriguez@uam.edu.co](mailto:alfonso.rodriguez@uam.edu.co) (A.J. Rodriguez-Morales), [vbenites@usil.edu.pe](mailto:vbenites@usil.edu.pe) (V.A. Benites-Zapata).

<https://doi.org/10.1016/j.tmaid.2021.102059>

Received 9 March 2021; Received in revised form 6 April 2021; Accepted 7 April 2021

Available online 16 April 2021

1477-8939/© 2021 Elsevier Ltd. All rights reserved.

## 1. Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic continues to affect the population worldwide. On April 12, 2021, more than 136.2 million cases and more than 2.94 million deaths have been reported from COVID-19 globally [1]. Latin America and the Caribbean (LAC) is one of the regions with the highest number of cases and mortality from COVID-19. Vulnerability to the pandemic is being exacerbated by the structural challenges posed by poverty, severe inequality and the region's already insufficient social protection and health systems and safety nets [2]. For example, by April 12, 2021, countries in this region such as Brazil (2nd place: 353,137 deaths), Mexico (3rd place: 209,338 deaths), Colombia (11th place: 65,889), Argentina (13th place: 57,779) and Peru (15th place: 54,903), lead the count of deaths from COVID-19 in the world [1].

Vaccines are health technologies widely used for disease prevention, recognizing that their use reduces the number of deaths from preventable causes and costs in health systems [3–5]. They are considered a highly cost-effective measure in health, preventing two to three million deaths per year [6]. In the context of the COVID-19 pandemic, vaccines have been developed as an additional tool to reduce the impact of the infection due the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). To date, more than 50 vaccine candidates have been developed in the world against SARS-CoV-2 [7]. Some of them are already approved by the leading regulatory institutions such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA), allowing vaccination campaigns in several countries worldwide.

Even though vaccines are essential for controlling transmissible diseases such as COVID-19; the growing spread of anti-vaccine movements and mistrust towards immunization programs have undermined vaccine effectiveness during the last decades, a situation that has been identified by the World Health Organization (WHO) as one of the top 10 threats to global health [6]. There are different motivations for reluctance to vaccination, including fear of its adverse effects (FAE), misinformation about the vaccine and its effects, or distrust of medical personnel or the health system, among others [8]. Likewise, socio-demographic factors such as age, gender, and residence area could be associated differently with vaccine intention depending on the context where they are researched [9,10]. Although the pandemic has overwhelmed health systems resulting in high mortality and morbidity rates, surveys have identified vaccine-hesitant subgroups [9–12].

Vaccine hesitancy is not a new phenomenon and predates the pandemic. By June 2020, surveys carried in countries affected by the pandemic describe that around 20% would not be willing to be vaccinated against COVID-19 [9,13]. Among the arguments described, the possibility of adverse events due to the vaccine administration stands out [14]. So far, there is little evidence about the VI against COVID-19 in LAC, a region characterized by access barriers to achieving immunization coverage goals such as socioeconomic inequalities, the influence of beliefs and attitudes and FAE [15]. The determinants of the acceptance of vaccination are multiple and depend on the context in which they are evaluated [8]. Therefore, this study aimed to determine the prevalence of VI and FAE of the COVID-19 vaccine and its associated factors in LAC. This information is critical for designing targeted strategies and policies to increase the VI against COVID-19 in the region.

## 2. Methods

### 2.1. Study design and data sources

We conducted a secondary analysis of a database collected by the University of Maryland and the social network Facebook® (Facebook, Inc), based on a survey designed to evaluate the respondents' features in the context of the COVID-19 pandemic. The survey includes demographic information, contact report, self-report of COVID-19 symptoms, assessment of food and economic security, mental health and a

module on vaccination attitudes. The survey was conducted for the first time on April 23, 2020, and is conducted daily in more than 200 countries or territories translated into each country's primary language.

### 2.2. Population and sample

The surveyed population included participants aged 18 and over who were Facebook® users. For the analysis, we included the LAC participants who answered the survey from January 15 to February 1, 2021, reaching a total number of 784,460 adults. We excluded those participants who did not have the variables of interest for this analysis, for which we analyzed 472,521 adults from 20 LAC countries.

## 3. Variables

### 3.1. Outcomes

#### 3.1.1. Vaccination intention

We evaluated the VI using the following question: If a vaccine to prevent COVID-19 were offered to you today, would you choose to get vaccinated? This question had four possible answers: yes, definitely; yes, probably; no, probably and no, definitely. We dichotomized the variable considering the last two alternatives to the non-VI for COVID-19 and the first two alternatives as to the VI.

#### 3.1.2. Fear of adverse effects of vaccination

Besides, we evaluated the FAE of vaccination using the following question: How concerned are you that you would experience a side effect from a COVID-19 vaccination? This question had four possible answers: very concerned, moderately concerned, slightly concerned and not at all concerned. We dichotomized the variable considering the first four alternatives regarding the presence of FAE and the last alternative as the absence.

### 3.2. Independent variables

#### 3.2.1. Sociodemographic characteristics

We included gender (male, female, non-binary), age (18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75 or more years) and the residential area of the participant (city, town, rural area).

#### 3.2.2. COVID-19 symptoms and compliance with community mitigation strategies

We evaluated the presence of suspicious COVID-19 symptoms, defined as three or more of the following symptoms in the last 24 h: fever, cough, difficulty breathing, fatigue, nasal discharge, muscle pain, sore throat, chest pain, nausea, loss of smell, eye pain, and headache.

We included compliance with the three main community mitigation strategies: hand washing, use of a mask, and physical distancing. We defined the compliance with physical distancing when the participant reported not having been in direct contact (including touching, shaking hands, hugging, kissing) for no more than 1 min in the last 24 h and not having been within 2 m of any person with whom you are not currently living. We considered handwashing compliance when participants reported having washed their hands at least once in the last 24 h. Besides, we considered a mask using compliance when participants reported wearing it in public (at least once) during the last seven days. We created a variable considering compliance with the three community mitigation strategies.

#### 3.2.3. Food and economic insecurity

Food security was assessed by the following question: How worried are you about having enough to eat in the next week? This question had four possible answers: very worried, somewhat worried, not very worried, and not worried at all. The variable was dichotomized, considering the first three alternatives as food insecurity.

Financial security was assessed by the following question: How worried are you about your household's finances in the next month? This question had four alternatives: very worried, somewhat worried, not very worried, and not worried at all. The variable was dichotomized, considering the first three responses as economic insecurity.

### 3.2.4. Mental health evaluation

We evaluated the presence of depressive symptoms using the following question adapted from the Kessler Psychological Distress Scale (K10): In the past seven days, how often did you feel so depressed that nothing could cheer you up? This question had five possible answers: all the time, most of the time, some of the time, a little of the time and none of the time [16]. We generated a dichotomous variable considering the last alternative as the absence of depressive symptoms and the first four alternatives regarding the presence of depressive symptoms.

We included evaluating anxiety symptoms, measured by the following question adapted from the Kessler Psychological Distress Scale (K10): During the last seven days, how often did you feel so nervous that nothing could calm you down? This question had five alternatives: all the time, most of the time, some of the time, a little of the time and none of the time [16]. We generated a dichotomous variable considering the last alternative as the absence of anxiety symptoms and the other four alternatives to the presence of anxiety symptoms.

Likewise, we evaluated the participant's fear to become seriously ill or his fear that a family member would become seriously ill from COVID-19, which was evaluated using the following question: How worried are you that you or someone in your immediate family might become seriously ill from coronavirus (COVID-19)? The question had the following possible answers: very worried, somewhat worried, not too worried and not worried at all. We created a dichotomous variable considering the last alternative as the absence of fear of the participant or a family member would become seriously ill from COVID-19 and the remaining three as the presence of fear.

### 3.2.5. Probability of vaccination acceptance when recommended by different stakeholders

We assessed the influence that friends and family, local health workers, the World Health Organization (WHO), government health officials, and politicians could have on the participants VI. That was evaluated using the following question: would you be more or less likely to get a COVID-19 vaccination if it were recommended to you by each of the following. These questions had three answers: more likely, about the same and less likely. We considered the last two alternatives as to the lack of influence for the VI and the first alternative to influence the VI.

### 3.3. Statistical analysis

We downloaded the Microsoft Excel® 2010 format database and imported it into the statistical package STATA® v14.0 (StataCorp, TX, USA). We carried out the statistical analyses considering the complex sampling of the survey using the svy command.

We described the qualitative variables using absolute frequencies and weighted proportions according to the survey's complex sampling with their respective 95% confidence intervals (95%CI). Likewise, we performed the bivariate analysis between the covariates of interest and the outcome variables, using Pearson's Chi-square test with Rao-Scott correction. Also, we performed generalized linear models from the Poisson family with a logarithmic link function to evaluate the factors associated with VI and FAE. We calculated crude (cPR) and adjusted (aPR) prevalence ratios with their 95%CI. We used a statistical criterion ( $p < 0.05$ ) to select the variables for the adjusted model. Also, we evaluated the possible collinearity between the covariates included in the final model.

### 3.4. Ethical considerations

The participants gave informed consent before starting the survey. The study is exempt from an institutional review board ethical approval since it used secondary data, and the database does not contain any sensitive data or personal identifiers. Hence, the integrity of the participants was not compromised. We obtained the data by signing a research data use agreement with the University of Maryland. The data was downloaded without identifiers. The participants gave their informed consent before starting the survey.

## 4. Results

### 4.1. Characteristics of the study sample

We analyzed a sample of 472,521 LAC adults from January 15 to February 1, 2021. We found that 49.6% ( $n = 205,569$ ) were male, 65.9% ( $n = 331,835$ ) were under 45 years of age and 79.4% ( $n = 390,122$ ) lived in a city. Likewise, 22.3% ( $n = 110,075$ ) had suspicious symptoms of COVID-19, while 49.8% ( $n = 236,617$ ) complied with the community mitigation strategies, 71.2% ( $n = 328,732$ ) had food insecurity and 85.3% ( $n = 401,377$ ) had economic insecurity. 95.1% ( $n = 453,513$ ) reported fear to get seriously ill or that a member of their family would be seriously ill from COVID-19, as well as 43.9% ( $n = 219,796$ ) had anxiety symptoms. 41.6% ( $n = 198,556$ ) and 60.3% ( $n = 298,914$ ) reported that the recommendation by family and friends, as well as local doctors could influence their VI, respectively. We found that 80.0% ( $n = 391,597$ ) reported VI and 81.2% ( $n = 382,507$ ) had FAE (Table 1).

### 4.2. Bivariate analysis according to vaccination intention and fear of adverse effects of the vaccine

We found statistically significant differences between the VI and the included covariates, except for food insecurity ( $p = 0.554$ ) (Table 2). Likewise, we found statistically significant differences between FAE and the independent variables included, except for compliance with community mitigation strategies ( $p = 0.530$ ) (Table 3). The bivariate analysis, according to the outcomes, is described in Tables 2 and 3

### 4.3. Prevalence of vaccination intention by country

The countries with the highest prevalence of VI were Mexico (88.4%), Puerto Rico U.S. (85.0%), Costa Rica (84.1%), Brazil (83.1%) and Honduras (80.5%). On the other hand, those with the lowest prevalence of VI were Haiti (43.2%), Paraguay (64.6%), Dominican Republic (65.8%), Uruguay (65.9%) and Venezuela (68.8%) (Fig. 1).

### 4.4. Prevalence of fear to adverse effects of the vaccine according to countries

We found that the countries with the highest prevalence of FAE were Venezuela (92.7%), Bolivia (91.3%), Ecuador (90.9%), Peru (90.5%) and the Dominican Republic (90.3%). On the other hand, those with the lower frequency of FAE were Brazil (68.2%), Costa Rica (79.8%), Puerto Rico, U.S. (80.8%), Argentina (84.5%) and Paraguay (84.5%) (Fig. 1).

### 4.5. Probability of vaccination intention when recommended by different stakeholders

The countries with the highest prevalence of VI based on the recommendation of friends and family were Mexico (49.1%), Puerto Rico (47.1%) and Nicaragua (47.0%). Also, the countries with the highest prevalence of VI based on the recommendation of local health workers were Brazil (69.1%), Costa Rica (66.9%) and Puerto Rico (66.1%). The countries with the highest prevalence of VI based on the recommendation by the WHO were Brazil (73.8%), Mexico (73.6%) and

**Table 1**  
Descriptive analysis of the study sample (n = 472,521).

Characteristics	Total		
	Absolute frequency of participants surveyed	Weighted proportion according to each category	
	n	%	95%CI
Gender			
Male	205,569	49.6	49.0–50.1
Female	263,026	49.4	48.9–50.0
Non-binary	3926	1.0	0.9–1.1
Age (years)			
18–24	86,687	19.5	18.6–20.3
25–34	134,279	25.9	25.2–26.5
35–44	110,869	20.5	20.2–20.9
45–54	76,091	17.6	17.2–17.9
55–64	46,323	9.8	9.3–10.4
65–74	15,592	5.9	5.4–6.5
75 years or older	2680	0.9	0.8–1.0
Living area			
City	390,122	79.4	75.8–82.6
Town	53,353	13.2	10.7–16.2
Village or rural area	29,046	7.4	6.5–8.4
COVID-19 symptomatology			
No	362,446	77.7	76.6–78.8
Yes	110,075	22.3	21.2–23.4
Compliance with community mitigation strategies			
No	235,904	50.2	49.1–51.4
Yes	236,617	49.8	48.6–50.9
Food insecurity			
No	143,789	28.8	27.1–30.5
Yes	328,732	71.2	69.5–72.9
Economic insecurity			
No	71,144	14.7	14.1–15.4
Yes	401,377	85.3	84.6–85.9
Fear of becoming seriously ill or that a family member becomes seriously ill from COVID-19			
No	19,008	4.9	4.1–6.0
Yes	453,513	95.1	94.7–95.5
Anxiety symptomatology			
No	252,725	56.1	55.2–57.1
Yes	219,796	43.9	42.9–44.8
Depressive symptomatology			
No	238,497	52.7	51.8–53.6
Yes	234,024	47.3	46.4–48.2
Probability of vaccination acceptance when recommended by friends and family			
Less likely/about the same	273,965	58.4	57.2–59.6
More likely	198,556	41.6	40.4–42.8
Probability of vaccination acceptance when recommended by local health workers			
Less likely/about the same	173,607	39.7	37.2–42.3
More likely	298,914	60.3	57.7–62.8
Probability of vaccination acceptance when recommended by the WHO			
Less likely/about the same	150,856	34.4	31.9–36.9
More likely	321,665	65.6	63.1–68.1
Probability of vaccination acceptance when recommended by government health officials			
Less likely/about the same	234,300	51.4	49.5–53.2
More likely	238,221	48.6	46.8–50.5
Probability of vaccination acceptance when recommended by politicians			
Less likely/about the same	423,381	89.8	89.3–90.3
More likely	49,140	10.2	9.7–10.7
Vaccination intention			
No	80,924	20.0	18.4–21.7
Yes	391,597	80.0	78.3–81.6

**Table 1 (continued)**

Characteristics	Total		
	Absolute frequency of participants surveyed	Weighted proportion according to each category	
	n	%	95%CI
Fear of adverse effects of vaccination			
No	90,014	18.9	15.8–22.2
Yes	382,507	81.2	77.8–84.2

95%CI: 95% confidence intervals; WHO: World Health Organization.

Costa Rica (66.9%) and Puerto Rico (66.4%). Furthermore, the countries with the highest prevalence of VI based on the recommendation by the government health officials were Costa Rica (62.0%), Mexico (56.0%) and Puerto Rico (54.5%). Finally, the countries with the highest prevalence of VI based on the recommendation by politicians were Puerto Rico (17.7%), Haiti (16.4%) and Costa Rica (13.2%) (Fig. 2 and supplementary material).

**4.6. Factors associated with the vaccination intention**

In the adjusted regression model, we found that female gender (aRP = 0.97; 95%CI: 0.95–0.97; p < 0.001) and non-binary gender (aRP = 0.93; 95%CI: 0.90–0.95; p < 0.001), compared to males, were associated with a lower prevalence of VI. Likewise, living in a village or rural area (aRP = 0.96; 95%CI: 0.95–0.97; p < 0.001) was associated with a lower probability of VI when compared to a city. Also, compliance with community mitigation strategies (aRP = 0.99; 95%CI: 0.98–0.99; p = 0.008) was associated with a lower prevalence of VI. Likewise, being afraid of getting seriously ill or being afraid that a family member would get seriously sick from COVID-19 (aRP = 1.28; 95%CI: 1.26–1.30; p < 0.001) and displaying depressive symptoms (aRP = 1.03; 95%CI: 1.03–1.04; p < 0.001), were all associated with a higher prevalence of VI. We found that the recommendations of family and friends (aRP = 1.08; 95%CI: 1.07–1.09; p < 0.001), local doctors (aRP = 1.29; 95%CI: 1.26–1.31; p < 0.001), WHO (aRP = 1.44; 95%CI: 1.41–1.47; p < 0.001) and government health officials (aRP = 1.10; 95%CI: 1.09–1.11; p < 0.001) were associated with a higher probability of VI, while the recommendations by politicians (aRP = 0.93; 95%CI: 0.92–0.94; p < 0.001), was associated with a lower probability of VI (Table 4).

**4.7. Factors associated with fear of adverse effects of the vaccine in the study sample**

In the adjusted regression model, we found that female gender (aRP = 1.07; 95%CI: 1.06–1.07; p < 0.001) and non-binary gender (aRP = 1.04; 95%CI: 1.01–1.06; p = 0.001), compared to the male gender, were associated with a higher prevalence of FAE. Likewise, living in a town (aRP = 1.08; 95%CI: 1.05–1.11; p < 0.001), village or rural area (aRP = 1.04; 95%CI: 1.02–1.06; p < 0.001), compared to a city, was associated with a greater frequency of FAE. In addition, economic insecurity (aRP = 1.16; 95%CI: 1.14–1.19; p < 0.001), fear of getting seriously ill or that a family member gets seriously sick from COVID-19 (aRP = 1.21; 95%CI: 1.19–1.23; p < 0.001), having suspicious symptoms of COVID-19 (aRP = 1.02; 95%CI: 1.01–1.03; p < 0.001) and having depressive symptoms (aRP = 1.01; 95%CI: 1.01–1.02; p = 0.018), were associated with a higher prevalence of FAE.

On the other hand, being between 25 and 34 years old (aRP = 1.01; 95%CI: 1.01–1.02; p < 0.001) compared to those aged 18–24 years, was associated with a greater probability of FAE. Likewise, 45–54 (aRP = 0.99; 95%CI: 0.98–0.99; p = 0.029), 55–64 (aRP = 0.96; 95%CI: 0.95–0.98; p = 0.001), 65–74 (aRP = 0.95; 95%CI: 0.93–0.97; p < 0.001), compared to those aged 18–24 years, was associated with a lower frequency of FAE. We found that recommendations from family

**Table 2**  
Descriptive and bivariate analysis of the study sample characteristics according to vaccination intention (n = 472,521).

Characteristics	Vaccination intention						P-value
	No			Yes			
	Absolute frequency of participants surveyed	Weighted proportion according to each category		Absolute frequency of participants surveyed	Weighted proportion according to each category		
	n	%	95%CI	n	%	95%CI	
Gender							<0.001
Male	33,117	19.1	17.8–20.4	172,452	80.9	79.6–82.2	
Female	46,758	20.7	18.6–23.0	216,268	79.2	77.0–81.4	
Non-binary	1049	29.8	26.9–31.8	2877	70.2	67.2–73.1	
Age (years)							0.004
18–24	14,068	20.1	18.1–22.3	72,619	79.9	77.7–81.9	
25–34	22,560	20.7	18.9–22.7	111,719	79.3	77.3–81.1	
35–44	19,145	19.9	18.5–21.4	91,724	80.1	78.6–81.5	
45–54	13,525	19.7	18.0–21.4	62,566	80.3	78.6–82.0	
55–64	8274	19.0	17.7–20.4	38,049	81.0	79.6–82.3	
65–74	2783	18.8	17.3–20.5	12,809	81.2	79.5–82.7	
75 years or older	569	22.3	20.0–24.8	2111	77.7	75.2–80.0	
Living area							<0.001
City	64,081	19.0	17.5–20.7	326,041	81.0	79.3–82.5	
Town	10,260	22.5	20.2–25.0	43,093	77.5	75.0–79.8	
Village or rural area	6583	25.8	24.2–27.6	22,463	74.2	72.4–75.8	
COVID-19 symptomatology							<0.001
No	62,748	20.3	18.7–21.9	299,698	79.7	78.1–81.3	
Yes	18,176	19.1	17.4–20.8	91,899	80.9	79.2–82.6	
Compliance with community mitigation strategies							0.005
No	39,073	19.6	17.8–21.4	196,831	80.4	78.6–82.2	
Yes	41,851	20.4	18.9–22.0	194,766	79.6	78.0–81.1	
Food insecurity							0.554
No	23,755	19.8	17.9–21.8	120,034	80.2	78.2–82.1	
Yes	57,169	20.1	18.5–21.7	271,563	79.9	78.3–81.5	
Economic insecurity							<0.001
No	12,652	21.5	19.7–23.5	58,492	78.5	76.5–80.3	
Yes	68,272	19.7	18.2–21.4	333,105	80.3	78.6–81.8	
Fear of becoming seriously ill or that a family member becomes seriously ill from COVID-19							<0.001
No	7942	44.7	42.9–46.5	11,066	55.3	53.5–57.1	
Yes	72,982	18.7	17.2–20.4	380,531	81.3	79.6–82.8	
Anxiety symptomatology							<0.001
No	49,705	22.4	20.8–24.1	203,020	77.6	75.9–79.2	
Yes	31,219	16.9	15.3–18.6	188,577	83.1	81.4–84.7	
Depressive symptomatology							<0.001
No	45,844	22.0	20.5–23.5	192,653	78.0	76.5–79.5	
Yes	35,080	17.8	16.1–19.7	198,944	82.2	80.3–83.9	
Probability of vaccination acceptance when recommended by friends and family							<0.001
Less likely/about the same	65,346	27.6	25.5–29.9	208,619	72.4	70.1–74.5	
More likely	15,578	9.2	8.4–10.1	182,978	90.8	89.9–91.6	
Probability of vaccination acceptance when recommended by local health workers							<0.001
Less likely/about the same	66,128	41.4	39.6–43.3	107,479	58.6	56.7–60.4	
More likely	14,796	5.8	5.3–6.5	284,118	94.2	93.5–94.7	
Probability of vaccination acceptance when recommended by the WHO							<0.001
Less likely/about the same	63,448	45.6	44.3–47.0	87,408	54.4	53.0–55.7	
More likely	17,476	6.6	5.9–7.3	304,189	93.4	92.7–94.1	
Probability of vaccination acceptance when recommended by government health officials							<0.001
Less likely/about the same	72,026	34.5	32.6–36.4	162,274	65.5	63.6–67.4	
More likely	8898	4.7	4.2–5.2	229,323	95.3	94.8–95.8	
Probability of vaccination acceptance when recommended by politicians							<0.001
Less likely/about the same	78,518	21.5	19.8–23.3	344,863	78.5	76.7–80.2	
More likely	2406	6.6	5.7–7.7	46,734	93.4	92.3–94.3	

95%CI: 95% confidence intervals, WHO: World Health Organization.

and friends (aRP = 1.04; 95%CI: 1.03–1.05; p < 0.001) were associated with a higher prevalence of FAE, while recommendations by local doctors (aRP = 0.92; 95%CI: 0.90–0.94; p < 0.001), WHO (aRP = 0.91; 95%CI: 0.88–0.95; p < 0.001), government health officials (aRP = 0.96; 95%CI: 0.95–0.97; p < 0.001) and politicians (aRP = 0.90; 95%CI: 0.89–0.91; p < 0.001), was associated with a lower probability of FAE

(Table 4).

According to the countries included, the proportion of vaccination intention and fear to adverse effects of vaccination is available in the [Supplementary Table S1](#). According to the countries included, the proportion of influence on the vaccination intention is described in [Table S2](#).

**Table 3**  
Descriptive and bivariate analysis of the study sample characteristics according to the fear of vaccination's adverse effects (n = 472,521).

Characteristics	Fear of adverse effects of vaccination						P-value
	No			Yes			
	Absolute frequency of participants surveyed	Weighted proportion according to each category		Absolute frequency of participants surveyed	Weighted proportion according to each category		
	n	%	95%CI	n	%	95%CI	
Gender							<0.001
Male	45,310	21.9	18.9–25.2	160,259	78.1	74.8–81.1	
Female	44,083	15.6	12.6–19.3	218,943	84.4	80.7–87.4	
Non-binary	621	16.7	13.8–20.1	3305	83.3	79.9–86.2	
Age (years)							<0.001
18–24	15,320	16.9	14.3–19.8	71,367	83.1	80.2–85.7	
25–34	23,231	16.1	13.5–19.2	111,048	89.9	80.8–86.5	
35–44	21,131	18.3	15.3–21.8	89,738	81.7	78.2–84.5	
45–54	15,388	20.0	16.8–23.7	60,703	80.0	76.3–83.2	
55–64	10,632	23.3	19.5–27.6	35,691	76.7	72.4–80.5	
65–74	3667	25.6	22.1–29.5	11,925	74.4	70.5–77.9	
75 years or older	645	24.5	20.8–28.6	2035	75.5	71.4–79.2	
Living area							<0.001
City	78,884	20.1	16.8–23.9	311,238	78.9	76.1–83.2	
Town	6668	12.2	11.4–13.0	46,685	87.8	87.0–88.6	
Village or rural area	4462	15.8	14.3–17.6	24,584	84.2	82.4–85.7	
COVID-19 symptomatology							<0.001
No	72,735	19.7	16.6–23.3	289,711	80.3	76.7–83.4	
Yes	17,279	15.5	13.0–18.3	92,796	84.5	81.7–87.0	
Compliance with community mitigation strategies							0.530
No	44,971	18.8	15.7–22.4	190,933	81.2	77.6–84.3	
Yes	45,043	18.7	15.8–22.0	191,574	81.3	78.0–84.2	
Food insecurity							<0.001
No	41,840	29.4	25.4–33.7	101,949	70.6	66.3–74.6	
Yes	48,174	14.5	12.1–17.2	280,558	85.5	82.8–87.9	
Economic insecurity							<0.001
No	22,045	31.5	27.7–35.5	49,099	68.5	64.5–72.3	
Yes	67,969	16.6	13.8–19.8	333,408	83.4	80.2–86.2	
Fear of becoming seriously ill or that a family member becomes seriously ill from COVID-19							<0.001
No	6375	33.9	32.1–35.6	12,633	66.1	64.4–67.9	
Yes	83,639	18.0	14.9–21.6	369,874	82.0	78.4–85.1	
Anxiety symptomatology							<0.001
No	52,593	20.7	17.8–23.9	200,132	79.3	76.1–82.2	
Yes	37,421	16.3	13.1–20.0	182,375	83.7	80.0–86.9	
Depressive symptomatology							<0.001
No	49,055	20.6	17.7–23.7	189,442	79.4	76.3–82.3	
Yes	40,959	16.7	13.5–20.5	193,065	83.3	79.5–86.5	
Probability of vaccination acceptance when recommended by friends and family							<0.001
Less likely/about the same	49,925	17.6	14.8–20.9	224,040	82.4	79.1–85.2	
More likely	40,089	20.3	17.1–24.0	158,467	79.7	76.0–82.9	
Probability of vaccination acceptance when recommended by local health workers							<0.001
Less likely/about the same	19,756	11.3	10.4–12.7	153,851	88.7	87.3–89.9	
More likely	70,258	23.6	19.8–27.9	228,656	76.4	72.1–80.2	
Probability of vaccination acceptance when recommended by the WHO							<0.001
Less likely/about the same	16,221	10.9	10.1–11.7	134,635	89.1	88.3–89.9	
More likely	73,793	22.9	19.0–27.3	247,872	77.1	72.7–81.0	
Probability of vaccination acceptance when recommended by government health officials							<0.001
Less likely/about the same	32,012	13.4	11.3–15.8	202,288	86.6	84.2–88.7	
More likely	58,002	24.4	20.7–28.6	180,219	75.6	71.4–79.3	
Probability of vaccination acceptance when recommended by politicians							<0.001
Less likely/about the same	74,713	17.4	14.5–20.7	348,668	82.6	79.3–85.5	
More likely	15,301	31.0	27.3–35.0	33,839	69.0	65.0–72.7	

95%CI: 95% confidence intervals; WHO: World Health Organization.

## 5. Discussion

### 5.1. Main findings

This work aimed to evaluate the prevalence and factors associated with VI and FAE. The findings show that approximately eight out of ten

participants had VI; however, there was a similar FAE frequency. Furthermore, we found that female and non-binary participants had a lower probability of VI. On the other hand, the fear of becoming seriously ill or that a family member becomes seriously ill from COVID-19, having depressive symptoms, and the recommendations from family and friends, local health workers, WHO and government health officials




Fig. 1. Prevalence of vaccination intention and fear of adverse effects of the vaccine according to Latin American and the Caribbean.




Fig. 2. Prevalence of the vaccination intention after the recommendation by: (A). Friends and family; (B). Local health workers; (C). The World Health Organization; (D). Government health officials; (E). Politicians.

were associated with a higher prevalence of VI. However, recommendations from politicians were associated with a lower probability of VI.

Besides, we found that female or non-binary gender living in a town, village or rural area was associated with a higher FAE prevalence. On the other hand, being over 35 years of age was associated with a lower probability of FAE and, in contrast, economic insecurity, fear of becoming seriously ill, or a family member becoming seriously ill from COVID-19 and depressive symptoms with a greater probability of FAE. Finally, friends and family's recommendations were associated with a higher probability of FAE. In contrast, recommendations by local health workers, WHO, government health officials, and politicians were associated with a lower frequency of FAE. The current study is one of the first aiming to evaluate the VI in the LAC region; the findings can help identify higher-risk groups to design targeted strategies to increase VI and reduce FAE.

### 5.2. Comparison with previous studies

To date, most studies have been conducted in North America [17–20], Europe [11,21,22], Asia [23,24] and Australia [25]. In general terms, our results show a higher prevalence of VI in the LAC region compared to its peers. However, some studies have found that almost 84% of Chinese adults were willing to receive a COVID-19 vaccine [23]. This prevalence is higher than the reported in our study for Brazil and

Honduras, which were in our top five countries with the highest VI. Regarding the associated factors, our study shows that women were less likely to accept a COVID-19 vaccine as in Europe [11,22], Australia [25], and the US [17]. Similarly, fear or perceived severity of COVID-19 [18,19] and healthcare providers' recommendations also increased the probability of VI in some studies conducted in US adults [19].

On the other hand, even though the fear of adverse effects has been described as an essential barrier to vaccination for COVID-19 [26], we found few studies assessing this topic [27,28]. Although associated factors were not evaluated, it has been reported that fear of adverse effects was the leading cause for rejecting the COVID-19 vaccine. Similar conclusions were reported during and after outbreaks of vaccine-preventable diseases [29–31]. Recently in another cross-sectional study in Colombia, assessing perceptions of COVID-19 vaccination among physicians found that around 91% of them are willing to get vaccinated [32].

### 5.3. Interpretation of the results

We found that female and non-binary genders, compared to males, were associated with a lower probability of VI and a higher probability of FAE. This finding goes in line with previous studies [10,18,33–35], where males had a greater frequency of VI; this might be explained by several factors such as the exposure that mothers have to anti-vaxxer

**Table 4**

Crude and adjusted generalized linear models of the Poisson family with a logarithmic link to evaluate the factors associated with vaccination intention and the fear of adverse effects of vaccination in the study sample.

Characteristics	Vaccination intention						Fear of adverse effects of vaccination					
	Crude			Adjusted			Crude			Adjusted		
	cPR	95%CI	P value	aPR	95%CI	P value	cPR	95%CI	P value	aPR	95%CI	P value
Gender												
Male	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Female	0.98	0.96–0.99	0.026	0.97	0.95–0.97	<0.001	1.08	1.07–1.09	<0.001	1.07	1.06–1.07	<0.001
Non-binary	0.87	0.84–0.90	<0.001	0.93	0.90–0.95	<0.001	1.07	1.03–1.10	<0.001	1.04	1.01–1.06	0.001
Age (years)												
18–24	Reference	–	–				Reference	–	–	Reference	–	–
25–34	0.99	0.98–1.00	0.059				1.00	1.00–1.02	0.002	1.01	1.01–1.02	<0.001
35–44	1.00	0.99–1.01	0.622				0.98	0.97–0.99	0.001	1.00	0.99–1.01	0.707
45–54	1.01	0.99–1.02	0.394	Not included <sup>a</sup>			0.96	0.95–0.98	<0.001	0.99	0.98–0.99	0.029
55–64	1.01	1.00–1.03	0.075				0.92	0.90–0.94	<0.001	0.96	0.95–0.98	0.001
65–74	1.02	1.00–1.04	0.088				0.89	0.87–0.92	<0.001	0.95	0.93–0.97	<0.001
75 years or older	0.97	0.94–1.00	0.059				0.91	0.88–0.94	<0.001	0.97	0.94–1.00	0.077
Living area												
City	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Town	0.96	0.93–0.98	0.001	1.00	0.98–1.01	0.659	1.10	1.06–1.14	<0.001	1.08	1.05–1.11	<0.001
Village or rural area	0.92	0.90–0.93	<0.001	0.96	0.95–0.97	<0.001	1.05	1.02–1.09	0.001	1.04	1.02–1.06	<0.001
COVID-19 symptomatology												
No	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Yes	1.02	1.01–1.02	<0.001	1.00	1.00–1.01	0.148	1.05	1.04–1.07	<0.001	1.02	1.01–1.03	<0.001
Compliance with community mitigation strategies												
No	Reference	–	–	Reference	–	–	Reference	–	–	Not included <sup>a</sup>		
Yes	0.99	0.98–0.99	0.003	0.99	0.98–0.99	0.008	1.00	1.00–1.01	0.541			
Food insecurity												
No	Reference	–	–	Not included <sup>b</sup>			Reference	–	–	Not included <sup>b</sup>		
Yes	1.00	0.98–1.01	0.549				1.21	1.17–1.25	<0.001			
Economic insecurity												
No	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Yes	1.02	1.01–1.03	<0.001	0.99	0.99–1.00	0.072	1.22	1.19–1.25	<0.001	1.16	1.14–1.19	<0.001
Fear of becoming seriously ill or that a family member becomes seriously ill from COVID-19												
No	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Yes	1.47	1.43–1.51	<0.001	1.28	1.26–1.30	<0.001	1.24	1.21–1.27	<0.001	1.21	1.19–1.23	<0.001
Anxiety symptomatology												
No	Reference	–	–	Not included <sup>c</sup>			Reference	–	–	Not included <sup>c</sup>		
Yes	1.07	1.06–1.08	<0.001				1.06	1.05–1.06	<0.001			
Depressive symptomatology												
No	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
Yes	1.05	1.05–1.06	<0.001	1.03	1.03–1.04	<0.001	1.05	1.04–1.06	<0.001	1.01	1.01–1.02	0.018
Probability of vaccination acceptance when recommended by friends and family												
Less likely/about the same	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
More likely	1.25	1.23–1.28	<0.001	1.08	1.07–1.09	<0.001	0.98	0.96–0.98	<0.001	1.04	1.03–1.05	<0.001
Probability of vaccination acceptance when recommended by local health workers												
Less likely/about the same	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
More likely	1.61	1.57–1.65	<0.001	1.29	1.26–1.31	<0.001	0.86	0.83–0.90	<0.001	0.92	0.90–0.94	<0.001
Probability of vaccination acceptance when recommended by the WHO												
Less likely/about the same	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
More likely	1.72	1.68–1.76	<0.001	1.44	1.41–1.47	<0.001	0.87	0.83–0.91	<0.001	0.91	0.88–0.95	<0.001

(continued on next page)



Table 4 (continued)

Characteristics	Vaccination intention						Fear of adverse effects of vaccination					
	Crude			Adjusted			Crude			Adjusted		
	cPR	95%CI	P value	aPR	95%CI	P value	cPR	95%CI	P value	aPR	95%CI	P value
Probability of vaccination acceptance when recommended by government health officials												
Less likely/about the same	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
More likely	1.46	1.42–1.49	<0.001	1.10	1.09–1.11	<0.001	0.87	0.85–0.90	<0.001	0.96	0.95–0.97	<0.001
Probability of vaccination acceptance when recommended by politicians												
Less likely/about the same	Reference	–	–	Reference	–	–	Reference	–	–	Reference	–	–
More likely	1.19	1.17–1.21	<0.001	0.93	0.92–0.94	<0.001	0.83	0.82–0.85	<0.001	0.90	0.89–0.91	<0.001

95%CI: 95% confidence intervals; cPR: Crude prevalence ratio; aPR: Adjusted prevalence ratio; WHO: World Health Organization.

<sup>a</sup> Not included due to not having a statistically significant association in the crude model.

<sup>b</sup> Not included due to collinearity with economic insecurity.

<sup>c</sup> Not included due to collinearity with the fear of becoming ill or that a family member could become seriously ill from COVID-19.

groups, the exclusion of pregnant and lactating women in the COVID-19 vaccine trials and the, as well as men having a lower acceptance of conspiracy beliefs about the disease [10,34,36]. In LAC, man's role as family chief has been described [37,38]; besides, to a growing financial crisis given the pandemic's economic insecurity, the most vulnerable groups require urgent access to the vaccine to be able to sustain their households [9]. Economic insecurity was associated with a higher prevalence of FAE; in contrast, high vaccination coverage would be necessary to reactivate economic activities. Therefore, it urges to design and implement effective communication strategies to increase the population's confidence in COVID-19 vaccination while refuting falsehoods about the vaccine effects and other conspiracy theories [18]. Other possible causes of a low VI frequency could be the belief that vaccines are unnecessary and the unknown or short duration of immunity [12].

Furthermore, we found that living in towns, village or rural areas was associated with a greater FAE frequency, a finding that seems to be consistent with previous studies [10]. Distrust in vaccines and conspiracy beliefs are more robust in people with lower education levels and regions with higher poverty rates [39–41], such as LAC's rural regions. In these areas, health promotion activities do not have adequate coverage increasing the risk of misinformation; therefore, increasing resistance to immunization strategies and community mitigation strategies. It is necessary to reinforce and adapt communication strategies towards these populations [39].

LAC is one of the most affected regions by the pandemic; some of these countries rank among the countries reporting the most coronavirus-related deaths per inhabitant in the world. The pandemic effects have been devastating for their health systems, which in many cases are fragmented and nowadays have collapsed [40]. The collapse of the healthcare system leads to fear of suffering severe COVID-19 disease, for which vaccination represents the hope of being able to defeat the pandemic and reduce the high mortality rates [41]. After witnessing the positive outcomes of experiences such as the Israeli one [42], the message on the need for LAC countries of a high coverage campaign for COVID19 has been reinforced, which would explain the high frequency of VI. However, this occurs with a high frequency of FAE, which persists in the population due to mistrust regarding vaccines' safety and the short time these products were developed [43].

We found that the recommendation by friends and family increased the VI, but also the FAE. This situation could be due to the immediate environment's information to contain fake news or non-corroborated

information that would generate mistrust [43,44]. Likewise, excessive exposure to false and fatalistic news can generate resistance to vaccination and lead to vaccination rejection [39]. However, given the need to return to daily activities and observing that the number of people vaccinated increases in developed countries, the desire to have vaccines soon could become more assertive.

Also, we found that a recommendation from local health workers, government health officials and WHO increases the VI and decreases the FAE. That is important to identify groups that could potentially serve as communication agents to increase vaccination acceptance in the population. Due to the health systems' inadequate response capacity during the pandemic, the self-medication practice gained popularity [45]. There is a vast culture of self-medication in the LAC region, which is even promoted by communication media. Besides, in countries as Peru and Bolivia, the use of unproven therapies such as chlorine dioxide became relevant, increasing the popularity of extremist anti-vaccine groups [46]. It is relevant to have community strategies based on scientific information and adapted according to the population group of interest [47,48]. The health personnel and the minister of health of each country must provide confidence to the population and communicate the vaccination benefits [43,49].

We find that politicians recommendations decreased the VI and FAE. This situation could be due to the population believes that the measures taken to combat the pandemic have been affected by political decisions or by personal pursuits objectives by political groups [43]. In this way, there was a politicization of the pandemic, which generates distrust in the population at a government's sanitary recommendation [18]. However, due to the constant corruption scandals to which the LAC political class has been linked, including clandestine vaccination, outside the context of a clinical trial and influence traffic such as Peru and Argentina [50,51]. These events would generate rejection towards vaccination but the loss of FAE.

We found differences in the prevalence of VI and FAE among countries. Likewise, the high frequency of VI was not consistent with the low frequency of FAE in all countries. Only Puerto Rico U.S., Costa Rica and Brazil had the highest VI with the lowest FAE presence among the countries. These countries were also the ones with the highest frequency of VI after a recommendation of the WHO, local health workers and government officials. Thus, it is likely that sociocultural factors, the dissemination of information campaigns by the government, the strength of the anti-vaxer movements and the politicization of

vaccination can influence the differences in VI and FAE in other countries [12,36].

#### 5.4. The relevance of our findings

It is important to identify groups that may have less VI or greater FAE to intervene rapidly. The best strategy to control the pandemic is mass vaccination; many countries have already started the vaccination process, prioritizing vulnerable groups [52]. Although the VI prevalence is high, the FAE frequency is similar, which could compromise LAC countries' national immunization strategies. Besides, LAC countries have a more substantial vaccination scheme than European or North American countries [15]; therefore, vaccination campaigns and strategies could be successful, and the population could accept them.

During the COVID-19 pandemic, due to the disease's fear, the population used multiple information resources, including television, radio, social media, local doctors and scientists who did scientific divulgation [43]. However, due to the pandemic's spread, the lack of adequate and accessible treatment, and the media's contradictions, the population achieved an "infodemic" [53,54]. This situation led to the belief in uncorroborated information that could generate mistrust or rejection of COVID-19 vaccines. In this way, it is crucial to work on disseminating transparent and adequate information regarding vaccines' safety and efficacy with local doctors, health officials, and scientists who can provide confidence to the population [43,47]. Likewise, it is crucial to prevent political corruption acts concerning vaccines' proper use from generating rejection in the population. International health agencies, including the WHO, and especially the Pan American Health Organization (PAHO), should consider these results to promote vaccination in the region of the Americas.

#### 5.5. Strengths and limitations

The study has limitations. Although the data collected from a multinational study with a significant sample was analyzed, the participants are users of a network, which implies that the data obtained comes from a sample with internet access and social media users, not representing a population without these characteristics. Likewise, the variables included for this analysis and its definition are subordinated to the survey. Additionally, there may be other confounders for the association between the variables studied and the VI or FAE, which were not measured by the survey and should be included in future studies. Besides, the data was obtained by self-report, so there may be a sub-record of information. Finally, due to the study's design, causality between the variables evaluated cannot be established. Despite this, this study has strengths such as the large sample that includes 20 LAC countries, which characterizes the study's problem for this population. Likewise, the respondents are users of social media widely known and used in LAC (and four out of every five Internet users in this region have a Facebook profile). Also, as a limitation, we have no access to variables such as racial and ethnic minorities, and certainly, possible variation in uptake based on race and ethnicity would be present, as has been previously reported [55].

## 6. Conclusions

Despite the high prevalence of VI, the study found a similar FAE frequency. The identified factors can be used to design and develop strategies to promote vaccination, aiming to reduce the FAE. Guaranteeing a mass vaccination to reduce the human impact of COVID-19 is essential. Moreover, when people are suffering the neglect in LAC, and support the return of economic activities.

### Ethical approval

Not required as a retrospective analysis of data, blinded personal

identification data. The participants gave informed consent before starting the survey. The study is exempt from an institutional review board ethical approval since it used secondary data, and the database does not contain any sensitive data or personal identifiers. Hence, the integrity of the participants was not compromised. We obtained the data by signing a research data use agreement with the University of Maryland. The data was downloaded without identifiers. The participants gave their informed consent before starting the survey.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Authors' contributions

All authors made substantial contributions to the study's conception and design, analysis and interpretation. CRediT author statement:

### CRediT authorship contribution statement

**Diego Urrunaga-Pastor:** Conceptualization, Methodology, Writing – original draft. **Guido Bendezu-Quispe:** Conceptualization, Methodology, Writing – original draft. **Percy Herrera-Añazco:** Conceptualization, Methodology, Writing – original draft. **Angela Uyen-Cateriano:** Methodology, Writing – review & editing. **Carlos J. Toro-Huamanchumo:** Conceptualization, Methodology, Writing – original draft. **Alfonso J. Rodriguez-Morales:** Methodology, Writing – original draft, Writing – review & editing. **Adrian V. Hernandez:** Methodology, Writing – review & editing. **Vicente A. Benites-Zapata:** Conceptualization, Methodology, Writing – original draft.

### Declaration of competing interest

The authors declare that they have no competing interests.

### Acknowledgements

The authors would like to thank the University of Maryland and Facebook, Inc for conducting and made the survey dataset available.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tmaid.2021.102059>.

### References

- [1] Johns Hopkins University. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). <https://coronavirus.jhu.edu/map.html>; 2021.
- [2] CEPAL N. Health and the economy: a convergence needed to address COVID-19 and retake the path of sustainable development in Latin America and the Caribbean 2020.
- [3] Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, et al. Economic evaluation of the routine childhood immunization program in the United States, 2009. *Pediatrics* 2014;133:577–85. <https://doi.org/10.1542/peds.2013-0698>.
- [4] Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low- and middle-income countries, 2011–20. *Health Aff Proj Hope* 2016;35:199–207. <https://doi.org/10.1377/hlthaff.2015.1086>.
- [5] Orenstein WA, Ahmed R. Simply put: vaccination saves lives. *Proc Natl Acad Sci U S A* 2017;114:4031–3. <https://doi.org/10.1073/pnas.1704507114>.
- [6] World Health Organization. Ten threats to global health in 2019. <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>. [Accessed 10 February 2021].
- [7] World Health Organization. COVID-19 vaccines. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines>. [Accessed 9 February 2021].
- [8] World Health Organization. Vaccine hesitancy: a growing challenge for immunization programmes. <https://www.who.int/news/item/18-08-2015-vaccin>

- e-hesitancy-a-growing-challenge-for-immunization-programmes. [Accessed 10 February 2021].
- [9] Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* 2020;1–4. <https://doi.org/10.1038/s41591-020-1124-9>.
  - [10] Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. *Vaccines* 2021;9:160.
  - [11] Peretti-Watel P, Seror V, Cortaredona S, Launay O, Raude J, Verger P, et al. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. *Lancet Infect Dis* 2020;20:769–70. [https://doi.org/10.1016/S1473-3099\(20\)30426-6](https://doi.org/10.1016/S1473-3099(20)30426-6).
  - [12] Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: a rapid systematic review. *Vaccines* 2021;9:16.
  - [13] Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. *PLoS Neglected Trop Dis* 2020;14:e0008961. <https://doi.org/10.1371/journal.pntd.0008961>.
  - [14] Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be ready for it? *Int J Publ Health* 2020;1–2. <https://doi.org/10.1007/s00038-020-01404-4>.
  - [15] Guzman-Holst A, DeAntonio R, Prado-Cohrs D, Juliao P. Barriers to vaccination in Latin America: a systematic literature review. *Vaccine* 2020;38:470–81. <https://doi.org/10.1016/j.vaccine.2019.10.088>.
  - [16] Andrews G, Slade T. Interpreting scores on the Kessler psychological distress scale (K10). *Aust N Z J Publ Health* 2001;25:494–7.
  - [17] Latkin CA, Dayton L, Yi G, Colon B, Kong X. Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US. *PLoS One* 2021;16:e0246970.
  - [18] Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: results of a nationwide survey. *Vaccine* 2021;39:1080–6. <https://doi.org/10.1016/j.vaccine.2021.01.010>.
  - [19] Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated? *Vaccine* 2020;38:6500–7. <https://doi.org/10.1016/j.vaccine.2020.08.043>.
  - [20] Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJ. A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2. *Front Psychol* 2020;11:2890.
  - [21] Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. *Hum Vaccines Immunother* 2020;1–10.
  - [22] Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communications. *Lancet Reg Health-Eur* 2021;1:100012.
  - [23] Chen M, Li Y, Chen J, Wen Z, Feng F, Zou H, et al. An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination. *Hum Vaccines Immunother* 2021;1–10.
  - [24] Yu Y, Lau JT, Lau M, Wong M, Chan PK. Understanding the prevalence and associated factors of behavioral intention of COVID-19 vaccination under specific scenarios combining effectiveness, safety, and cost in the Hong Kong Chinese general population. *Int J Health Pol Manag* 2021. <https://doi.org/10.34172/ijhpm.2021.02>. In press.
  - [25] Rhodes A, Hoq M, Measey M-A, Danchin M. Intention to vaccinate against COVID-19 in Australia. *Lancet Infect Dis* 2020. [https://doi.org/10.1016/S1473-3099\(20\)30724-6](https://doi.org/10.1016/S1473-3099(20)30724-6). In press.
  - [26] Fisk RJ. Barriers to vaccination for COVID-19 control—experience from the United States. *Glob Health J* 2021;5(1):51–5. <https://doi.org/10.1016/j.glohj.2021.02.005>.
  - [27] Scott EM, Stein R, Brown MF, Hershberger J, Scott EM, Wenger OK. Vaccination patterns of the northeast Ohio Amish revisited. *Vaccine* 2021;39:1058–63.
  - [28] Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, et al. Once we have it, will we use it?: In: A European survey on willingness to be vaccinated against COVID-19. Springer; 2020.
  - [29] Fournet N, Mollema L, Ruijs WL, Harmsen IA, Keck F, Durand JY, et al. Under-vaccinated groups in Europe and their beliefs, attitudes and reasons for non-vaccination; two systematic reviews. *BMC Publ Health* 2018;18:1–17.
  - [30] Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999–2000. *Emerg Infect Dis* 2002;8:1442.
  - [31] Rachiotis G, Mouchtouri VA, Kremastinou J, Gourgoulakis K, Hadjichristodoulou C. Low acceptance of vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in Greece. *Euro Surveill* 2010;15:19486.
  - [32] Alvarado-Socarras JL, Vesga-Varela AL, Quintero-Lesmes DC, Fama-Pereira MM, Serrano-Diaz NC, Vasco M, et al. Perception of COVID-19 vaccination amongst physicians in Colombia. *Vaccines* 2021;9(3):287. <https://doi.org/10.3390/vaccines9030287>.
  - [33] Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* 2020;26:100495.
  - [34] Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum Vaccines Immunother* 2020;16:2204–14.
  - [35] Abu-Farha RK, Alzoubi KH, Khabour OF. Public willingness to participate in COVID-19 vaccine clinical trials: a study from Jordan. *Patient Prefer Adherence* 2020;14:2451.
  - [36] Sallam M, Dababseh D, Eid H, Al-Mahzoum K, Al-Haidar A, Taim D, et al. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: a study in Jordan and Kuwait among other Arab countries. *Vaccines* 2021;9:42.
  - [37] Wilson TD. Violence against women in Latin America. *Lat Am Perspect* 2014;41:3–18. <https://doi.org/10.1177/0094582X13492143>.
  - [38] Bott S, Guedes A, Goodwin M, Mendoza JA. Violence against women in Latin America and the Caribbean: a comparative analysis of population-based data from 12 countries. Washington, DC: Pan American Health Organization; 2012. <https://stacks.cdc.gov/view/cdc/22295>. [Accessed 2 March 2021].
  - [39] French J, Deshpande S, Evans W, Obregon R. Key guidelines in developing a pre-emptive COVID-19 vaccination uptake promotion strategy. *Int J Environ Res Publ Health* 2020;17:5893. <https://doi.org/10.3390/ijerph17165893>.
  - [40] Atun R, de Andrade LOM, Almeida G, Cotlear D, Dmytraczenko T, Frenz P, et al. Health-system reform and universal health coverage in Latin America. *Lancet* 2015;385:1230–47. [https://doi.org/10.1016/S0140-6736\(14\)61646-9](https://doi.org/10.1016/S0140-6736(14)61646-9).
  - [41] Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* 2020;1–4. <https://doi.org/10.1038/s41591-020-1124-9>.
  - [42] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med* 2021. <https://doi.org/10.1056/NEJMoa2101765>. 0:null.
  - [43] Mannan DKA, Farhana KM. Knowledge, attitude and acceptance of a COVID-19 vaccine: a global cross-sectional study. Rochester, NY: Social Science Research Network; 2020. <https://doi.org/10.2139/ssrn.3763373>.
  - [44] Ali SH, Foreman J, Tozan Y, Capasso A, Jones AM, DiClemente RJ. Trends and predictors of COVID-19 information sources and their relationship with knowledge and beliefs related to the pandemic: nationwide cross-sectional study. *JMIR Public Health Surveill* 2020;6:e21071. <https://doi.org/10.2196/21071>.
  - [45] Molento MB. COVID-19 and the rush for self-medication and self-dosing with ivermectin: a word of caution. *One Health* 2020;10:100148. <https://doi.org/10.1016/j.onehlt.2020.100148>.
  - [46] Mostajo-Radji M. Pseudoscience in the times of crisis: how and why chlorine dioxide consumption became popular in Latin America during the COVID-19 pandemic. <https://doi.org/10.31235/osf.io/u9ehf>; 2020.
  - [47] Qiao S, Friedman DB, Tam CC, Zeng C, Li X. Vaccine acceptance among college students in South Carolina: do information sources and trust in information make a difference? *MedRxiv* 2020. <https://doi.org/10.1101/2020.12.02.20242982>. 2020.12.02.20242982.
  - [48] Charron J, Gautier A, Jestin C. Influence of information sources on vaccine hesitancy and practices. *Med Maladies Infect* 2020;50:727–33. <https://doi.org/10.1016/j.medmal.2020.01.010>.
  - [49] Alvarado-Socarras JL, Vesga-Varela AL, Quintero-Lesmes DC, Fama-Pereira MM, Serrano-Diaz NC, Vasco M, et al. Perception of COVID-19 vaccination amongst physicians in Colombia, January. 2021 2021.
  - [50] Chauvin L. Peruvian COVID-19 vaccine scandal spreads. *Lancet* 2021;397:783. [https://doi.org/10.1016/S0140-6736\(21\)00508-0](https://doi.org/10.1016/S0140-6736(21)00508-0).
  - [51] Lissardy G. Escándalos con la vacuna del coronavirus: cómo la lucha contra la covid-19 desnuda viejos vicios de América Latina. *BBC News Mundo*; 2021.
  - [52] Los países de América Latina donde todavía no han llegado vacunas contra covid-19 (y cuándo se espera que lo hagan). *BBC News Mundo*; 2021.
  - [53] Patwa P, Sharma S, Pykl S, Guptha V, Kumari G, Akhtar MS, et al. Fighting an infodemic: COVID-19 fake news dataset. 2020. *ArXiv201103327 Cs*.
  - [54] Alvarez-Risco A, Mejia CR, Delgado-Zegarra J, Del-Aguila-Arcentales S, Arce-Esquivel AA, Valladares-Garrido MJ, et al. The Peru approach against the COVID-19 infodemic: insights and strategies. *Am J Trop Med Hyg* 2020:tpmd200536.
  - [55] Tirupathi R, Muradova V, Shekhar R, Salim SA, Al-Tawfiq JA, Palabindala V. COVID-19 disparity among racial and ethnic minorities in the US: a cross sectional analysis. *Trav Med Infect Dis* 2020;38:101904.